Shares of Cytokinetics Inc. (CYTK) surged over 5% on Thursday after analysts initiated coverage on the biopharmaceutical company with upbeat ratings and price targets.
RBC Capital Markets kicked off coverage on Cytokinetics with an Outperform rating and a $80 price target, representing substantial upside from current levels. In a research note, RBC analysts cited the company's promising pipeline of cardiovascular therapies as a key driver for their bullish outlook.
Several other firms also weighed in with positive commentary on Cytokinetics and the broader healthcare sector. The flurry of optimistic analyst views fueled investor enthusiasm, propelling CYTK shares to close 5.02% higher at $54.00 on the day.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。